DelveInsight’s “Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Sickle Cell Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Sickle Cell Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Sickle Cell Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Sickle Cell Disease: An Overview
Sickle cell disease (SCD) is a group of inherited red blood cell disorders caused by a structural abnormality of hemoglobin called sickle hemoglobin (HbS) which encodes hemoglobin subunit β. HbS is inherited in an autosomal recessive way and can occur due to homozygosity for HbS (HbSS). HbS is functional and soluble when oxygenated, but upon deoxygenation it polymerizes, leading to the generation of deformed red blood cells known as sickle cells and dense erythrocytes. Hence, the sickle cells die early, which causes a constant shortage of red blood cells.
There are several types of Sickle Cell Disease. The specific type of Sickle Cell Disease depends on the genes the person inherits from their parents. The most common types of Sickle Cell Disease include HbSS (commonly called sickle cell anemia and is usually the most severe form of the disease), HbSC (a milder form of SCD), and HbS beta-thalassemia (a milder form of SCD). Management of Sickle Cell Disease is focused on preventing and treating pain episodes and other complications. Prevention strategies include lifestyle behaviors and medical screening and interventions to prevent Sickle Cell Disease complications.
The current therapies used to prevent the complications of the disease vary in their effectiveness and are associated with severe risks and tolerability issues. Besides this, Sickle Cell Disease presents with large unmet medical needs, with no disease-modifying treatment. Several drugs are approved for treating Sickle Cell Disease including ADAKVEO, DROXIA, ENDARI, and OXBRYTA.
Sickle Cell Disease Market Key Facts
-
As per a study by Wastnedge et al. (2018), the global meta-estimate for the birth prevalence of homozygous sickle cell disease was 111.91 per 100,000 live births, and that for heterozygous sickle cell disease was 4229.72 per 100,000, and it was least in Europe, i.e., 803.57 per 100,000 live births.
-
A study by Leleu et al. (2021), from a cross-sectional observational study including French Sickle Cell Disease patients followed up between 2011 and 2016, estimated that Sickle Cell Disease prevalence in France is between 19,800 and 32,400 patients in 2016. The median age was 31 to 33, significantly less than the median age of 41 in the country’s general population.
-
A study by Sundd et al. (2018), quoted that Sickle Cell Disease affects approximately 100,000 people in the United States and millions worldwide. Additionally, approximately 3.2 million people live with Sickle Cell Disease, 43 million people have sickle cell trait (i.e., are carriers of the mutation), and 176,000 people die of Sickle Cell Disease-related complications per year.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Sickle Cell Disease pipeline therapies. It also thoroughly assesses the Sickle Cell Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Sickle Cell Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Sickle Cell Disease Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Sickle Cell Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Sickle Cell Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Sickle Cell Disease Epidemiology, Segmented as –
-
Total Prevalent Cases of Sickle Cell Disease (SCD) in the 7MM (2019-32)
-
Diagnosed Prevalent Cases of Sickle Cell Disease (SCD) in the 7MM (2019-32)
-
Type-specific Cases of Sickle Cell Disease (SCD) in the 7MM (2019-32)
-
Treated Cases of Sickle Cell Disease (SCD) in the 7MM (2019-32)
Sickle Cell Disease Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Sickle Cell Disease market or expected to be launched during the study period. The analysis covers the Sickle Cell Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Sickle Cell Disease drugs based on their sale and market share.
The report also covers the Sickle Cell Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Sickle Cell Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Sickle Cell Disease Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/sickle-cell-disease-market
Sickle Cell Disease Therapeutics Analysis
The current therapies used to prevent the complications of the disease vary in their effectiveness and are associated with serious risks and tolerability issues. Besides this, Sickle Cell Disease presents with large unmet medical needs, with no disease-modifying treatment. Several drugs are approved for the treatment of Sickle Cell Disease including ADAKVEO, DROXIA, ENDARI, and OXBRYTA. To further improve the treatmnet scenario, several major pharma and biotech companies are developing therapies for Sickle Cell Disease. Currently, Vertex Pharmaceuticals is leading the therapeutics market with its Sickle Cell Disease drug candidates in the most advanced stage of clinical development.
Sickle Cell Disease Companies Actively Working in the Therapeutics Market Include
-
Cellectis
-
Sana Biotechnology
-
Global Blood Therapeutics, Inc.
-
CSL Behring
-
Pfizer
-
Aruvant Sciences
-
Graphite Bio
-
Novartis
-
Agios Pharmaceuticals
-
Forma therapeutics
-
Vertex Pharmaceuticals
-
Global Blood Therapeutics, Inc.
-
Alfasigma
-
Novo Nordisk
-
bluebird bio
-
ExCellThera
-
Gamida Cell
-
KM Biologics/Takeda
-
Editas Medicine
And Many Others
Emerging and Marketed Sickle Cell Disease Therapies Covered in the Report Include:
-
BPX-501 T cells: Bellicum Pharmaceuticals
-
Canakinumab: Novartis
-
EPI01: Novo Nordisk
-
CTX001: Vertex Pharmaceuticals
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/sickle-cell-disease-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Sickle Cell Disease Competitive Intelligence Analysis
4. Sickle Cell Disease Market Overview at a Glance
5. Sickle Cell Disease Disease Background and Overview
6. Sickle Cell Disease Patient Journey
7. Sickle Cell Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Sickle Cell Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Sickle Cell Disease Unmet Needs
10. Key Endpoints of Sickle Cell Disease Treatment
11. Sickle Cell Disease Marketed Therapies
12. Sickle Cell Disease Emerging Drugs and Latest Therapeutic Advances
13. Sickle Cell Disease Seven Major Market Analysis
14. Attribute Analysis
15. Sickle Cell Disease Market Outlook (In US, EU5, and Japan)
16. Sickle Cell Disease Companies Active in the Market
17. Sickle Cell Disease Access and Reimbursement Overview
18. KOL Views on the Sickle Cell Disease Market
19. Sickle Cell Disease Market Drivers
20. Sickle Cell Disease Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/sickle-cell-disease-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Inguinal Hernia Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Inguinal Hernia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Inguinal Hernia market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/